The project aims to use models that describe clotting factor activity in blood after an infusion in patients with hemophilia to calculate their pharmacokinetics (PK). PK is used in this disease to help in selecting the right dose for the patient. The partnership with Hemalytic will provide them with necessary expertise in the use of these models. The PK model are central to the objective of analyzing data from various sources to assess the use of extended half-life clotting factor products in Canada. The intern will analyze real-world data from the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo.org) and the Canadian Blood Disorders Registry and integrate it with quality-of-life data from PROBE.